Oncolytics Biotech: Up on collaboration with Roche in cancer study

Oncolytics Biotech

27/10/2020 13:13

Oct 27 (Reuters) - ** U.S.-listed shares of the biotech
company  ONCY.O  rise 5% to a near five-month high of $2.32
premarket
    ** ONCY announces new early-to-mid stage trial testing its
experimental drug, pelareorep, in combination with Roche Holding
AG's  ROG.S  cancer treatment Atezolizumab in patients with
gastrointestinal cancer  urn:newsml:reuters.com:*:nCNW32jTra
    ** Says under the terms of the agreement, Roche will supply
Atezolizumab for use in ONCY's clinical development plan
    ** Study will be conducted at 25 centers in Germany with 55
patients planned for enrollment- co
    ** Up to Monday's close, stock was down 53.6% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))